1-15 of 15
Alexander Vorog
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Jorge E. Cortes, Michael W. Deininger, Jane Apperley, Chrisopher Kevin Arthur, Charles Chuah, Andreas Hochhaus, Hugues de Lavallade, Jeffrey H. Lipton, Elza Lomaia, James McCloskey, Michael J. Mauro, Beatriz Moiraghi, Carolina Pavlovsky, Gianantonio Rosti, Philippe Rousselot, Maria Undurraga, Lin Yang, Alexander Vorog, Tammie Yeh, L. Evan Reddick, Niti Patel, Hagop M. Kantarjian
Journal: Blood
Blood (2024) 144 (Supplement 1): 3148.
https://doi.org/10.1182/blood-2024-207634
Published: 2024
Journal Articles

Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

Elias Jabbour, Hagop M. Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica T. Leonard, David Gomez-Almaguer, Maria R. Baer, Carlo Gambacorti-Passerini, James McCloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Rocha, Philippe Rousselot, Pankit Vachhani, Eunice S. Wang, Lin Yang, Meliessa Hennessy, Alexander Vorog, Niti Patel, Tammie Yeh, Josep-Maria Ribera
Journal: Blood
Blood (2024) 144 (Supplement 1): 2821.
https://doi.org/10.1182/blood-2024-208504
Published: 2024
Journal Articles

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Jorge Cortes, Michael Deininger, Elza Lomaia, Beatriz Moiraghi, Soledad Undurraga, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Lori Maness, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane F Apperley
Journal: Blood
Blood (2023) 142 (Supplement 1): 3164.
https://doi.org/10.1182/blood-2023-178790
Published: 2023
Journal Articles

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Ibrahim Aldoss, Josep-Maria Ribera, Hagop Kantarjian, Pau Montesinos, Jessica T. Leonard, David Gomez-Almaguer, Maria R. Baer, Carlo Gambacorti-Passerini, James McCloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Rocha, Philippe Rousselot, Pankit Vachhani, Eunice S. Wang, Meliessa Hennessy, Niti Patel, Alexander Vorog, Bingxia Wang, Elias Jabbour
Journal: Blood
Blood (2023) 142 (Supplement 1): 2871.
https://doi.org/10.1182/blood-2023-179537
Published: 2023
Journal Articles

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Clinical Trials & Observations
Bruno Paiva, Irene Manrique, Meletios A. Dimopoulos, Francesca Gay, Chang-Ki Min, Sonja Zweegman, Ivan Špička, Raphael Teipel, María-Victoria Mateos, Nicola Giuliani, Michele Cavo, Christine Rojas Hopkins, Weijun Fu, Kaveri Suryanarayan, Alexander Vorog, Cong Li, Bingxia Wang, Jose Estevam, Richard Labotka, Ajeeta B. Dash
Journal: Blood
Blood (2023) 141 (6): 579–591.
https://doi.org/10.1182/blood.2022016782
Published: 2023
Includes: Supplemental data
Journal Articles

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Jane F. Apperley, Jorge E. Cortes, Elias Jabbour, Andreas Hochhaus, Timothy Hughes, Charles Chuah, Hugues de Lavallade, Michael W. Deininger, Jeffrey H. Lipton, Elza Lomaia, Lori Maness, Michael Mauro, James McCloskey, Beatriz Moiraghi, Carolina Pavlovsky, Christine Rojas, Philippe Rousselot, Tomasz Sacha, Moshe Talpaz, Anna Turkina, Maria Undurraga Sutton, Xiaowei Ren, Alexander Vorog, Gianantonio Rosti
Journal: Blood
Blood (2022) 140 (Supplement 1): 6760–6762.
https://doi.org/10.1182/blood-2022-157956
Published: 2022
Journal Articles

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Jorge E. Cortes, Michael W. Deininger, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Christine Rojas, Anna Turkina, Lori Maness, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane F. Apperley
Journal: Blood
Blood (2022) 140 (Supplement 1): 1495–1497.
https://doi.org/10.1182/blood-2022-157822
Published: 2022
Journal Articles

Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials

Elias J. Jabbour, Michael W. Deininger, Elisabetta Abruzzese, Jane F Apperley, Jorge E. Cortes, Charles Chuah, Daniel J. DeAngelo, John F. DiPersio, Andreas Hochhaus, Jeffrey H. Lipton, Franck E. Nicolini, Javier Pinilla Ibarz, Delphine Rea, Gianantonio Rosti, Philippe Rousselot, Michael J. Mauro, Neil P Shah, Moshe Talpaz, Alexander Vorog, Vickie Lu, Hagop Kantarjian
Journal: Blood
Blood (2021) 138 (Supplement 1): 2550.
https://doi.org/10.1182/blood-2021-146175
Published: 2021
Journal Articles

Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) By Baseline BCR-ABL1 Level and Baseline Mutation Status in the Optic Trial

Michael W. Deininger, Jane F Apperley, Christopher Kevin Arthur, Charles Chuah, Andreas Hochhaus, Hugues De Lavallade, Jeffrey H. Lipton, Elza Lomaia, James K McCloskey, Lori J. Maness, Michael J. Mauro, Beatriz Moiraghi, Carolina Pavlovsky, Gianantonio Rosti, Philippe Rousselot, Soledad S. Undurraga, Vickie Lu, Alexander Vorog, Jorge E. Cortes
Journal: Blood
Blood (2021) 138 (Supplement 1): 307.
https://doi.org/10.1182/blood-2021-145995
Published: 2021
Journal Articles

Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)

Meletios A. Dimopoulos, S. Vincent Rajkumar, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, Maria-Victoria Mateos, Gareth J. Morgan, Arun Kumar, Kaveri Suryanarayan, Alexander Vorog, Andrew Fergus, Richard Labotka
Journal: Blood
Blood (2021) 138 (Supplement 1): 1656.
https://doi.org/10.1182/blood-2021-150476
Published: 2021
Journal Articles

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies

Wee-Joo Chng, Sagar Lonial, Gareth J. Morgan, Shinsuke Iida, Philippe Moreau, Shaji Kumar, Philip Twumasi-Ankrah, Arun Kumar, Ajeeta B. Dash, Alexander Vorog, Xiaoquan Zhang, Kaveri Suryanarayan, Richard Labotka, Meletios A. Dimopoulos, S. Vincent Rajkumar
Journal: Blood
Blood (2021) 138 (Supplement 1): 1678.
https://doi.org/10.1182/blood-2021-147838
Published: 2021
Journal Articles

Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts

Bruno Paiva, PhD, Irene Manrique, PhD, Nicola Giuliani, Michele Cavo, Christine Rojas, MD, Weijun Fu, MD PhD, María-Victoria Mateos, MD PhD, Meletios A Dimopoulos, Alexander Vorog, MD, Cong Li, PhD, Bingxia Wang, PhD, Richard J Labotka, MD, Ajeeta B Dash, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-136105
Published: 2020
Journal Articles

Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial

Sara Bringhen, MD, Luděk Pour, MD, Reuben Benjamin, MBBS, FRCPath, PhD, Sebastian Grosicki, MD PhD, Chang-Ki Min, MD PhD, Danielle Leao Cordeiro De Farias, MDMSc,MBA, Alexander Vorog, MD, Richard J Labotka, MD, Bingxia Wang, PhD, Dasha Cherepanov, Lauren E. Cain, MHS, ScM, PhD, Sudhakar Manne, S. Vincent Rajkumar, MD, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-136293
Published: 2020
Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1867.
https://doi.org/10.1182/blood-2019-125629
Published: 2019
Journal Articles

Association of Liver Iron Concentration Levels with Myocardial T2* Responses in Transfusion-Dependent Thalassemia Major Patients Treated with Deferasirox and Deferoxamine- Extension of Cordelia Study

Dudley J Pennell, John B Porter, Antonio Piga, Jackie Han, Alexander Vorog, Yesim Aydinok
Journal: Blood
Blood (2015) 126 (23): 2155.
https://doi.org/10.1182/blood.V126.23.2155.2155
Published: 2015